During the first four years of this funding period, The Ohio State University Comprehensive Cancer Center (OSUCCC) has experienced growth and expansion of its Programs, primarily related to the opening of the Arthur G. James Cancer Hospital and Research Institute (CHRI) in July, 1990. The OSUCCC organization reflects importance. The OSUCCC Director also serves as the CHRI Director and oversees the CHRI administration. Of the 68 OSU interdisciplinary academic Centers, it is the only one whose director has a direct reporting relationship to the President and Board of Trustees of the University. The OSUCCC organizational model links all of the OSUCCC research Programs to the respective cancer disease sites. This reflects the OSUCCC leadership's recognition that one of its primary responsibilities involves facilitating, expanding, and expediting translational research activities. This application will describe the past accomplishments and future plans of the thirteen OSUCCC Programs which are served by thirteen OSUCCC shared services. It will also describe future plans for the next funding period which include the development of a major new Program in human cancer genetics. The request for support described in this application is a strong attempt by OSUCCC leadership to recognize its responsibility to the national community of NCI approved cancer Centers during this difficult time of budgetary constraints for support of NCI Centers. Accordingly, the budget request in this competitive renewal application for Year 21 represents a reduction in the prior year CCSG support. The total five-year requested support represents only a 17 percent increase from the prior funding period which is less than what would be expected from inflationary increases alone. This has been accomplished through utilizing non-CCSG sources of support for the OSUCCC. But it has been achieved primarily as an expression of the OSUCCC's effort to try to weigh its individual Center needs with the needs of all the other NCI approved cancer Centers and the contracted ability of the NCI budget to provide this support. The OSUCCC is proud of its past accomplishments and enthusiastically welcomes the challenges and opportunities described in this application for further expansion during the next five-year funding period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-21
Application #
2086422
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1977-07-01
Project End
1999-06-30
Budget Start
1995-09-06
Budget End
1996-06-30
Support Year
21
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Chen, Zhong; Wu, Dayong; Thomas-Ahner, Jennifer M et al. (2018) Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13. Proc Natl Acad Sci U S A 115:6810-6815
Moshiri, Farzaneh; Salvi, Alessandro; Gramantieri, Laura et al. (2018) Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma. Oncotarget 9:15350-15364
Petrov, Brawnie; Aldoori, Ayat; James, Cindy et al. (2018) Bipolar disorder in youth is associated with increased levels of vitamin D-binding protein. Transl Psychiatry 8:61
Senaras, Caglar; Niazi, Muhammad Khalid Khan; Sahiner, Berkman et al. (2018) Optimized generation of high-resolution phantom images using cGAN: Application to quantification of Ki67 breast cancer images. PLoS One 13:e0196846
Kovac, Rachel L; Ballash, Gregory; Fenger, Joelle et al. (2018) Plasma cytokeratin-18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib. J Vet Intern Med 32:2061-2068
Locke, Landon W; Kothandaraman, Shankaran; Tweedle, Michael et al. (2018) Use of a leukocyte-targeted peptide probe as a potential tracer for imaging the tuberculosis granuloma. Tuberculosis (Edinb) 108:201-210
Neff, Robert; Rush, Craig M; Smith, Blair et al. (2018) Functional characterization of recurrent FOXA2 mutations seen in endometrial cancers. Int J Cancer 143:2955-2961
Comiskey Jr, D F; Jacob, A G; Sanford, B L et al. (2018) A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo. Oncogene 37:95-106
Dietrich, Sascha; Ole?, Ma?gorzata; Lu, Junyan et al. (2018) Drug-perturbation-based stratification of blood cancer. J Clin Invest 128:427-445
Tallarico, Michael; Foster, Jared C; Seisler, Drew et al. (2018) Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611). J Geriatr Oncol 9:321-328

Showing the most recent 10 out of 2602 publications